A Phase 1 Dose-Escalation & Expansion Study of Intratumorally Administered Dual STING Agonist (ONM-501) Alone & in Combination With Cemiplimab in Patients With Advanced Solid Tumors & Lymphomas
Time: 1:30 pm
day: Conference Day 1
Details:
- Overcoming challenges of early STING Agonists
- Review the development and mechanism of action of dual STING agonist ONM-501
- Examine phase 1 trial design and review of trial updates and safety
